Ankit Mahadevia compensation by year
Spero Therapeutics Summary Compensation Table · all 7 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|
| Salary | $389,574 | $465,000 | $497,083 | $536,667 | $590,417 | $633,750 | $379,220 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $254,000 | $508,000 |
| Stock awards | $0 | $0 | $285,023 | $0 | $1,300,000 | $1,499,998 | $999,998 |
| Option awards | $2,679,616 | $0 | $752,778 | $1,153,962 | $2,650,765 | $1,499,324 | $0 |
| Non-equity incentive | $114,000 | $255,750 | $250,000 | $424,049 | $327,618 | $342,900 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $1,087 | $574 | $792 | $6,110 | $6,245 | $9,733 | $498,687 |
| Total | $3,184,277 | $721,324 | $1,785,676 | $2,120,788 | $4,875,045 | $4,239,705 | $2,385,905 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Spero Therapeutics, Inc. DEF 14A filed April 16, 2024, accession 0001193125-24-097749, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Spero Therapeutics, Inc. filed document, accession 0001193125-24-097749. Every figure is read from that document and cited to the page and table it appears in. Filed April 16, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 531,914 | $781,914 | — |
| RSU | 100,626 | $147,920 | — |
| RSU | 39,109 | $57,490 | — |
| Option | 52,302 | — | $19.18 |
| Option | 101,687 | — | $11.18 |
| Option | 7,500 | — | $9.34 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Spero Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
6 Form 4 lines since the FY2023 proxy (filed April 16, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-08-28 | Sale | — | 6,572 | $1.97 | 703,294 |
| 2025-06-12 | Grant or award | — | 20,000 | $0.00 | 709,866 |
| 2025-02-05 | Sale | — | 13,959 | $0.78 | 745,126 |
| 2025-02-05 | Sale | — | 55,260 | $0.78 | 689,866 |
| 2024-08-27 | Sale | — | 5,912 | $1.35 | 759,085 |
| 2024-05-29 | Grant or award | — | 20,000 | $0.00 | 764,997 |
The 6 most recent of 6 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Spero Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Ankit Mahadevia · this page | Former President and Chief Executive Officer (6) | $2,385,905 |
| Satyavrat Shukla | President and Chief Executive Officer | $2,024,647 |
| Tamara Joseph | Former Chief Legal Officer (7) | $1,455,126 |
| Timothy Keutzer | Chief Operating Officer | $1,438,569 |
Board service
Spero Therapeutics board · FY2023–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $45,000 | $57,800 | — | $0 | $102,800 |
| FY2024 | $75,000 | $28,400 | — | $101,110 | $204,510 |
| FY2023 | $0 | $0 | $0 | — | — |
Each year as the company reported it in Spero Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Spero Therapeutics pays directors a $40,000 cash retainer and $20,000 in RSUs. As stated in Spero Therapeutics's FY2025 proxy.
Committees
Development
The full Spero Therapeutics compensation record
free company briefThis page is one person within Spero Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Spero Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.